Adrian Bot, M.D., Ph.D. is the Vice President and Global Head of Translational Medicine at Kite, a Gilead Company, developing genetically engineered cell products for oncology indications. Dr. Bot has more than 20 years of experience in biopharmaceutical industry with focus on discovery and development of immunotherapies. He obtained his M.D. in Romania in 1993 and his Ph.D. in Biomedical Sciences at Mount Sinai School of Medicine in New York in 1998.  Subsequently, he was a Guest Scientist at the Scripps Research Institute in La Jolla, California. Prior to his appointment as Chief Scientific Officer at Kite Pharma in 2011 and then Vice President of Translational Medicine where he contributed to the development of a first-in-class cell therapy product for cancer, Dr. Bot served in various senior R&D leadership positions at MannKind Corp and Alliance Pharmaceutical Corp, La Jolla, California. His prior and current activities and appointments include editorial boards (Journal of Immunology, International Reviews of Immunology), leadership appointments in global professional societies (Society for Immunotherapy of Cancer) and Advisory Boards (Elicio Therapeutics).